Cimetidine in the management of colorectal cancer: A survey of the knowledge and opinions of pharmacy students

This survey was conducted at Howard University (HU) College of Pharmacy as part of a Drug Information course, in which First-Year Pharmacy students learn how to perform literature search on a pharmacy topic and run a survey. A total of 42 student respondents participated in the survey. Nearly 64% (n=27) wrongly thought that cimetidine reduces the risk of colon cancer, while 57.1% (n=24) gave a wrong response that, even though cimetidine is FDA-approved for other indications, it can be taken for the prevention of colorectal cancer. Twenty-seven (64.3%) correctly believed that cimetidine is used for other health problems than colorectal cancer. The majority gave the correct response (n=25; 59.5%) that prescription medications are more useful than dietary supplements for the prevention of colorectal cancer. The highest number of correct responses (n=28; 66.7%) was obtained for the question of cimetidine passing through breast milk. The opinions of survey respondents were evenly divided in recommending cimetidine for the prevention of colorectal cancer (50%, n=21), and knowing someone or oneself taken for other than colorectal cancer (50%, n=21). Opinions varied unevenly for the other three opinion-based questions.